CHARACTERIZATION OF NEUROTENSIN-LIKE IMMUNOREACTIVITY IN HUMAN BASAL GANGLIA - INCREASED NEUROTENSIN LEVELS IN SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE

被引:30
|
作者
FERNANDEZ, A
JENNER, P
MARSDEN, CD
DECEBALLOS, ML
机构
[1] CSIC, INST CAJAL, DEPT NEUROPATHOL, NEURODEGENERAT GRP, E-28002 MADRID, SPAIN
[2] UNIV LONDON KINGS COLL, NEURODEGENERAT DIS RES CTR, DIV BIOMED SCI, PHARMACOL GRP, LONDON, ENGLAND
[3] UNIV LONDON, NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT CLIN NEUROL, LONDON, ENGLAND
关键词
NEUROTENSIN; BASAL GANGLIA; PARKINSONS DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC); RADIOIMMUNOASSAY (RIA);
D O I
10.1016/0196-9781(94)00141-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A method that combines high performance liquid chromatography with radioimmunoassay (HPLC/RIA) has been used to characterize neurotensin-like immunoreactivity (NT-IR) in the basal ganglia from control subjects and Parkinson's disease (PD) patients. In samples from the caudate nucleus and putamen, NT-IR eluted as two HPLC peaks. One was indistinguishable from the synthetic tridecapeptide, while the other peak corresponded to oxidized NT, as judged by its chromatographic behaviour and its reaction with the antiserum employed. There were marked discrepancies between the IR detected in crude extracts and that in HPLC purified samples. NT levels (HPLC/RIA) were unaltered in the caudate nucleus, putamen and both segments of the globus pallidus in the parkinsonian brain. In contrast, there was a two-fold increase in NT content: in both zona compacta and zona reticulata of the substantia nigra in PD patients compared to controls. Degeneration of the nigrostriatal pathway and/or prolonged antiparkinsonian treatment in PD appears to alter neurotensin levels in an attempt to activate the dopaminergic nigrostriatal pathway.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 24 条
  • [1] IRON HISTOCHEMISTRY OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MORRIS, CM
    EDWARDSON, JA
    NEURODEGENERATION, 1994, 3 (04): : 277 - 282
  • [2] NEURONAL HYPERTROPHY IN THE PARS RETICULATA OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    NEAL, JW
    PEARSON, RCA
    COLE, G
    POWELL, TPS
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1991, 17 (03) : 203 - 206
  • [3] MEAN VOLUME OF PIGMENTED NEURONS IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MOLLER, A
    ACTA NEUROLOGICA SCANDINAVICA, 1992, 85 : 37 - 39
  • [4] REDUCED AND OXIDIZED GLUTATHIONE IN THE SUBSTANTIA-NIGRA OF PATIENTS WITH PARKINSONS-DISEASE
    SOFIC, E
    LANGE, KW
    JELLINGER, K
    RIEDERER, P
    NEUROSCIENCE LETTERS, 1992, 142 (02) : 128 - 130
  • [5] LOSS OF INSULIN-RECEPTOR IMMUNOREACTIVITY FROM THE SUBSTANTIA-NIGRA PARS-COMPACTA NEURONS IN PARKINSONS-DISEASE
    MOROO, I
    YAMADA, T
    MAKINO, H
    TOOYAMA, I
    MCGEER, PL
    MCGEER, EG
    HIRAYAMA, K
    ACTA NEUROPATHOLOGICA, 1994, 87 (04) : 343 - 348
  • [6] IS THE VULNERABILITY OF NEURONS IN THE SUBSTANTIA-NIGRA OF PATIENTS WITH PARKINSONS-DISEASE RELATED TO THEIR NEUROMELANIN CONTENT
    KASTNER, A
    HIRSCH, EC
    LEJEUNE, O
    JAVOYAGID, F
    RASCOL, O
    AGID, Y
    JOURNAL OF NEUROCHEMISTRY, 1992, 59 (03) : 1080 - 1089
  • [8] THE COMBINED METHOD OF TRANSPLANTATION OF FETAL SUBSTANTIA-NIGRA AND STEREOTAXIC THALAMOTOMY FOR PARKINSONS-DISEASE
    WU, CY
    DEZHOU, M
    BAO, XF
    ZHANG, QL
    SUN, W
    LI, FZ
    ZHAO, JJ
    BRITISH JOURNAL OF NEUROSURGERY, 1994, 8 (06) : 709 - 716
  • [9] URIC-ACID IS REDUCED IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE - EFFECT ON DOPAMINE OXIDATION
    CHURCH, WH
    WARD, VL
    BRAIN RESEARCH BULLETIN, 1994, 33 (04) : 419 - 425
  • [10] PATHOLOGICAL-CHANGES IN DENDRITES OF SUBSTANTIA-NIGRA NEURONS IN PARKINSONS-DISEASE - A GOLGI-STUDY
    PATT, S
    GERTZ, HJ
    GERHARD, L
    CERVOSNAVARRO, J
    HISTOLOGY AND HISTOPATHOLOGY, 1991, 6 (03) : 373 - 380